RVD regimen
WikiDoc Resources for RVD regimen |
Articles |
---|
Most recent articles on RVD regimen Most cited articles on RVD regimen |
Media |
Powerpoint slides on RVD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on RVD regimen at Clinical Trials.gov Clinical Trials on RVD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on RVD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on RVD regimen Discussion groups on RVD regimen Patient Handouts on RVD regimen Directions to Hospitals Treating RVD regimen Risk calculators and risk factors for RVD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for RVD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Bortezomib/Dexamethasone/Lenalidomide Regimen; RVD; Velcade/Revlimid/Dexamethasone; VRD; VDR
Overview
RVD regimen refers to a treatment regimen consisting of a combination of revlimid (lenalidomide), velcade (bortezomib) and dexamethasone used in the treatment of multiple myeloma[1][2]
Regimen
RRevlimid (lenalidomide)
VVelcade (Bortezomib)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C; et al. (2014). "Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients". Leukemia. 28 (3): 690–3. doi:10.1038/leu.2013.335. PMID 24220275.
- ↑ "NCI Thesaurus".